You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Single-cell analysis, next-generation sequencing, and synthetic DNA have all been crucial to efforts to find antibodies that could neutralize SARS-CoV-2.
The synthetic biology firm had total revenues of $19.3 million and withdrew its financial guidance for fiscal year 2020 citing uncertainty caused by COVID-19.
The company — formerly called Expedeon — recently divested its proteomics and immunology businesses in order to focus on the manufacture and supply of synthetic DNA.
The Cambridge, UK-based gene synthesis firm plans to use the funds to accelerate development of its silicon platform and introduce a desktop device.
The DNA synthesis company priced shares of common stock at $28 and increased the expected proceeds from its stock offering to $130 million.
The offering of common stock will be the second for Twist this year and the third since the company made its initial public offering in October 2018.
On a conference call to discuss the firm's fiscal Q1 financial results, Twist executives detailed the firm's vision for near- and long-term growth.
The company booked a net loss of $55.6 million, or $1.69 per share, for the quarter which included litigation settlement expenses of $22.5 million.
A hearing scheduled for Friday, part of a lawsuit filed by Agilent was cancelled, leading to speculation the sides were close to a settlement.
The company recently changed its name from Expedeon following the sale of its immunology and proteomics businesses to Abcam.
Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.
Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.
A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.
In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.